Volume 10, Issue 40 (8-2020)                   NCMBJ 2020, 10(40): 37-50 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

safamanesh A, oryan S, Ahmadi R, parivar K. study of comparative effects of harmine and ghrelin agonist on insulin and c-peptide secretion. NCMBJ 2020; 10 (40) :37-50
URL: http://ncmbjpiau.ir/article-1-1313-en.html
Department of Animal Sciences, Faculty of Basic Sciences, Qom Branch, Islamic Azad University, Qom, Iran , ramahmd@yahoo.com
Abstract:   (2828 Views)
Aim and Background: The ability to secrete insulin from the islets of Langerhans on the one hand and suppress the factors that increase serum glucose concentrations on the other; It is very important in patients with metabolic disorders such as diabetes. The aim of this study was to compare the effects of harmine with ghrelin agonist (as a suppressor of insulin secretion) on insulin secretion and c-peptide in PANC-1 cell line and intracellular glucose concentration in HT1080 cell line.
 Materials and Methods: To do this, cell lines were purchased from the Iranian Genetic Resources Center and after cell passage and preparation, were treated with doses of 0/01, 0/1, 1, 10 and 100 μg /ml harmin and ghrelin agonists with doses of 0/05, 0/5, 5, 50 and 500 μg / ml. While performing MTT test, insulin secretion and c-peptide were measured by ELISA.
Results: The results showed that harmine dose-dependently increased insulin and c-peptide secretion as well as increased intracellular glucose and had the opposite effect of ghrelin agonist.
 Conclusion: Harmine analogues could be a unique therapeutic promise for human diabetes and possibly serve as inhibitors of ghrelin agonists.
 
Full-Text [PDF 5803 kb]   (1003 Downloads) |   |   Full-Text (HTML)  (2313 Views)  
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2020/10/4 | Accepted: 2020/08/31 | Published: 2020/08/31

References
1. Dezaki K, Sone H, Koizumi M, Nakata M, Kakei M, Nagai H, et al. Blockade of Pancreatic Islet–Derived Ghrelin Enhances Insulin Secretion to Prevent High-Fat Diet–Induced Glucose Intolerance. Diabetes [Internet]. 2006 Dec 1;55(12):3486 LP – 3493. Available from: http://diabetes.diabetesjournals.org/content/55/12/3486.abstract
2. Kulkarni RN, Roper MG, Dahlgren G, Shih DQ, Kauri LM, Peters JL, et al. Islet secretory defect in insulin receptor substrate 1 null mice is linked with reduced calcium signaling and expression of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)-2b and -3. Diabetes. 2004 Jun;53(6):1517–25.
3. Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med. 2014 Apr;31(4):403–11.
4. RUBENSTEIN AH, CLARK JL, MELANI F, STEINER DF. Secretion of Proinsulin C-Peptide by Pancreatic β Cells and its Circulation in Blood. Nature [Internet]. 1969 Nov 15;224:697. Available from: https://doi.org/10.1038/224697a0
5. Briggs D, Andrews Z. A Recent Update on the Role of Ghrelin in Glucose Homeostasis. Vol. 7, Current diabetes reviews. 2011. 201–207 p.
6. Kuhtreiber WM, Washer SLL, Hsu E, Zhao M, Reinhold P 3rd, Burger D, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med. 2015 Oct;32(10):1346–53.
7. Saad MF, Bernaba B, Hwu C-M, Jinagouda S, Fahmi S, Kogosov E, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab. 2002;87(8):3997–4000.
8. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol. 2002;14(7):555–60.
9. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083.
10. Salehi A, de la Cour CD, Håkanson R, Lundquist I. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept. 2004;118(3):143–50.
11. Sun Y, Asnicar M, Smith RG. Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology. 2007;86(3):215–28.
12. Van Der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426–57.
13. Kim M-S, Yoon C-Y, Park K-H, Shin C-S, Park K-S, Kim S-Y, et al. Changes in ghrelin and ghrelin receptor expression according to feeding status. Neuroreport. 2003;14(10):1317–20.
14. Kageyama H, Takenoya F, Shiba K, Shioda S. Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding. Neuropeptides. 2010;44(2):133–8.
15. Chen X, Ge Y-L, Jiang Z-Y, Liu C-Q, Depoortere I, Peeters TL. Effects of ghrelin on hypothalamic glucose responding neurons in rats. Brain Res. 2005;1055(1–2):131–6.
16. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol. 2006;494(3):528–48.
17. Solomon A, De Fanti BA, Martinez JA. The nucleus tractus solitari (NTS) participates in peripheral ghrelin glucostatic hunger signalling mediated by insulin. Neuropeptides. 2006;40(3):169–75.
18. Heijboer AC, Pijl H, Van den Hoek AM, Havekes LM, Romijn JA, Corssmit EPM. Gut–brain axis: regulation of glucose metabolism. J Neuroendocrinol. 2006;18(12):883–94.
19. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun. 2005 Jan;326(2):378–86.
20. Miralles A, Esteban S, Sastre-Coll A, Moranta D, Asensio VJ, García-Sevilla JA. High-affinity binding of β-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. Eur J Pharmacol. 2005;518(2–3):234–42.
21. Pimpinella G, Palmery M. Interaction of β-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett. 1995;189(2):121–4.
22. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High Constitutive Signaling of the Ghrelin Receptor—Identification of a Potent Inverse Agonist. Mol Endocrinol [Internet]. 2003 Nov 1;17(11):2201–10. Available from: http://dx.doi.org/10.1210/me.2003-0069
23. Ding Y, He J, Huang J, Yu T, Shi X, Zhang T, et al. Harmine induces anticancer activity in breast cancer cells via targeting TAZ. Int J Oncol [Internet]. 2019;54(6):1995–2004. Available from: https://doi.org/10.3892/ijo.2019.4777
24. Steiner DF, Oyer PE. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc Natl Acad Sci U S A [Internet]. 1967 Feb;57(2):473–80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16591494
25. Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou S, et al. Antitumor and neurotoxic effects of novel harmine derivatives and structure‐activity relationship analysis. Int J cancer. 2005;114(5):675–82.
26. Geng X, Ren Y, Wang F, Tian D, Yao X, Zhang Y, et al. Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy. Biochem Biophys Res Commun [Internet]. 2018;498(1):99–104. Available from: http://www.sciencedirect.com/science/article/pii/S0006291X18304613
27. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest [Internet]. 1975 Jun;55(6):1278–83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1133173
28. Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab [Internet]. 2010 Dec;12(12):1036–47. Available from: https://pubmed.ncbi.nlm.nih.gov/20977574
29. Waki H, Park KW, Mitro N, Pei L, Damoiseaux R, Wilpitz DC, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab. 2007 May;5(5):357–70.
30. Zhao T-J, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci. 2010;107(16):7467–72.
31. Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, Kangawa K, et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 2004 Dec;53(12):3142–51.
32. Ikezaki A, Hosoda H, Ito K, Iwama S, Miura N, Matsuoka H, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes. 2002 Dec;51(12):3408–11.
33. Tsubota Y, Owada-Makabe K, Yukawa K, Maeda M. Hypotensive effect of des-acyl ghrelin at nucleus tractus solitarii of rat. Neuroreport. 2005 Feb;16(2):163–6.
34. Colombo M, Gregersen S, Xiao J, Hermansen K. Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets. Pancreas. 2003 Aug;27(2):161–6.
35. Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia. 2009 May;52(5):739–51.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb